Biogen $3 billion dollar investment in Sage is on a drug that not only failed to reach endpoint but seemed to have side effects.
AV101 is back in play big time IMO.
Vtgn wants to use the same model that AXSM used to get more of the drug through blood brain barrier.
Funding has always handicapped VTGN. Now they can move forward with PH94 and the other drugs in the pipeline. That is my hope anyway.
VTGN has 4 potential blockbusters in a hot biotech segment. No guarantees any succeed but the published data must have optimistic to attract a $100 mil investment.
We asked to invest and were told it was oversold so we were not able to participate
I think financing was a 100 percent institutional deal. Can’t wait to see the terms. Have been invested here since 2016 and this is the best news and validation that the assets they have are valuable that I have seen.
News 
Market Data 
Discover 
AI
